Manhattan Biosolutions

Manhattan BioSolutions is a private, preclinical-stage biotech focused on developing a novel platform for next-generation antibody-drug conjugates (ADCs). The company leverages expertise in antibody engineering, linker chemistry, and payload design to create ADCs that aim to overcome key limitations of current therapies, such as toxicity and resistance. It has built a robust network of academic and institutional collaborations, secured significant non-dilutive grant funding, and is advancing a pipeline of ADC candidates targeting various cancers.

Proprietary next-generation ADC platform focusing on novel, conditionally cleavable linkers (e.g., legumain-cleavable) and strategic payloads (e.g., TOP1 inhibitors, taxoids) to improve tumor targeting, payload release specificity, and overcome therapy resistance.

Manhattan BioSolutions competes in the highly crowded and rapidly evolving ADC therapeutics space, facing competition from large pharma (e.g., AstraZeneca, Pfizer, Roche) and numerous biotechs. Its differentiation hinges on its specific linker chemistry and payload expertise, but it must demonstrate clear advantages over other next-generation platforms focused on similar goals of improving stability and targeting.